Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.06 - $27.5 $130,698 - $3.39 Million
-123,300 Reduced 79.62%
31,568 $35,000
Q2 2022

Aug 15, 2022

BUY
$1.04 - $2.14 $139,461 - $286,969
134,098 Added 645.63%
154,868 $187,000
Q1 2022

May 16, 2022

BUY
$2.08 - $12.2 $43,201 - $253,393
20,770 New
20,770 $45,000

Others Institutions Holding ALGS

About Aligos Therapeutics, Inc.


  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.